BlueHalo LLC

DUBLIN, Jan. 15, 2024 /PRNewswire/ -- The "Chronic Disease Markets for Sustained Released Injectables" report has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for chronic disease markets for sustained release injectables. Provider organization business managers, healthcare administrators and investors will also benefit from this study. Evolving Engineered Solutions Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less. What You Will Learn What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them? What are the major factors driving sustained release injectable drug demand? What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact? How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry? What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products? In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate? What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables? Key Topics Covered: Injectable Drug Market Dynamics The Trend toward Self-Administration Injectable Drug Formulation Technology Innovation in Injectable Device Designs Therapeutic Demand Drivers Market Factors Competitive Landscape Risk Factors Sustained Release - Branded Formulation Technologies Biodegradable Polymers Branded SR Formulation Technologies Physical Process Control Methods Sustained Release Injectables - Development Factors Formulation Factors Stability Lyophilization Packaging Administration Factors SR Injectables - Product Analysis & Market Sector Forecasts Addiction Naltrexone Diabetes Exenatide Infectious Disease Interferon Hormone Deficiency Estradiol Somatropin Testosterone Metabolic Diseases Acromegaly Neurology Oncology Leukemia Lymphoma Cytarabine Prostate Pain Management Reproductive Health Fertility Endometriosis Market Profiles Companies Mentioned Alkermes Amylin AntriaBio Ascendis Pharma AstraZeneca Aurobundo Avadel Biomarin Camurus Critical Pharmaceuticals DURECT Eli Lilly Enzon Ipsen Janssen NanOlogy Novartis OctoPlus Oakwood Laboratories/PharmaSophia Pacira PhaseBio Pharmaceuticals Recipharm AB Roche Sanofi Taiwan Liposome Company Xbrane Bipharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Photo Credit: BlueHalo, Alpine Advanced Materials The next generation of Intense Eye unmanned aerial system (UAS) platform from BlueHalo (Arlington, Va., U.S.) will incorporate an injection-molded chassis using HX5, a multiscale reinforced polymer from Alpine Advanced Materials (Alpine, Dallas, Texas, U.S.). HX5 has been tested against some of the harshest environments on Earth and was engineered to replace machined aerospace-grade aluminum, making the Intense Eye UAS stronger and lighter with increased efficiency and payload capacity. The Intense Eye UAS family is a 750-millimeter class 4 rotor vertical takeoff and landing (VTOL) UAS for dual-use in commercial and military operations. The system’s software and avionics are strengthened by BlueHalo’s artificial intelligence (AI) and machine learning (ML) technologies — providing autonomy, communications systems and swarm logic capabilities. “Through our strategic focus on small business partnerships, BlueHalo has worked closely with the Alpine team to develop a lighter, stronger, more capable UAS through injection molding engineering,” says James Batt, BlueHalo chief growth officer. “The next generation of our Intense Eye UAS product line features this innovative HX5 airframe in combination with BlueHalo’s industry-leading autonomy and AI/ML capabilities, providing new mission-critical solutions to warfighters and expanding opportunities for our commercial partners.” “This is a victory for injection-molded HX5, which is ideal for the drone industry for many reasons,” adds David Brantner, CEO of Alpine Advanced Materials. “Our engineering team worked closely with BlueHalo throughout the process, leveraging all of HX5’s material advantages to create an innovative, tough-to-kill unmanned aerial system designed for complex battlespace environments.” The BlueHalo team worked shoulder-to-shoulder with Alpine, collaborating throughout development to strengthen the frame design based on mold flow analysis to promote good fiber alignment and strength in critical areas. In addition to the mechanical and environmental benefits provided by using the HX5 polymer, the injection molding process has enabled BlueHalo to accelerate production and delivery. BlueHalo can modify the IE-V3 for custom applications, including autonomous swarming solutions, payload development and deployment, test targets, fire and rescue operations, atmospheric profiling, education and research and more.